Which has stronger valuation & earnings, SRRK or MPLT?

Scholar Rock is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A

Is SRRK or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Maplight Therapeutics N/A N/A N/A

Does the media refer more to SRRK or MPLT?

In the previous week, Scholar Rock had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 5 mentions for Scholar Rock and 1 mentions for Maplight Therapeutics. Scholar Rock's average media sentiment score of 0.46 beat Maplight Therapeutics' score of 0.34 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CGON or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Maplight Therapeutics N/A N/A N/A

Does the media refer more to CGON or MPLT?

In the previous week, CG Oncology had 7 more articles in the media than Maplight Therapeutics. MarketBeat recorded 8 mentions for CG Oncology and 1 mentions for Maplight Therapeutics. CG Oncology's average media sentiment score of 0.65 beat Maplight Therapeutics' score of 0.34 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, CNTA or MPLT?

Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Centessa Pharmaceuticals N/A N/A -$197.53M -$1.79 N/A Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A

Is CNTA or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Centessa Pharmaceuticals N/A -60.37% -44.17% Maplight Therapeutics N/A N/A N/A

Which has better earnings and valuation, ERAS or MPLT?

Erasca is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A

Is ERAS or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Maplight Therapeutics N/A N/A N/A

Does the media prefer ERAS or MPLT?

In the previous week, Erasca had 42 more articles in the media than Maplight Therapeutics. MarketBeat recorded 43 mentions for Erasca and 1 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.34 beat Erasca's score of 0.13 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 4 Very Positive mention(s) 3 Positive mention(s) 32 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, BLTE or MPLT?

Belite Bio is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.53 N/A Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A

Is BLTE or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Maplight Therapeutics N/A N/A N/A

Does the media refer more to BLTE or MPLT?

In the previous week, Belite Bio had 5 more articles in the media than Maplight Therapeutics. MarketBeat recorded 6 mentions for Belite Bio and 1 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.34 beat Belite Bio's score of 0.27 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Maplight Therapeutics (MPLT) Competitors

$35.99 -1.88 (-4.96%)

Closing price 04:00 PM Eastern

Extended Trading

$36.70 +0.70 (+1.96%)

As of 07:34 PM Eastern

Compare

MPLT vs. SRRK, CGON, CNTA, ERAS, and BLTE

Should you buy Maplight Therapeutics stock or one of its competitors? MarketBeat compares Maplight Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maplight Therapeutics include Scholar Rock (SRRK), CG Oncology (CGON), Centessa Pharmaceuticals (CNTA), Erasca (ERAS), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does Maplight Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Scholar Rock currently has a consensus target price of $56.00, suggesting a potential upside of 10.54%. Maplight Therapeutics has a consensus target price of $39.10, suggesting a potential upside of 8.64%. Given Scholar Rock's higher possible upside, equities analysts clearly believe Scholar Rock is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	5 Strong Buy rating(s)	3.13

In the previous week, Scholar Rock had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 5 mentions for Scholar Rock and 1 mentions for Maplight Therapeutics. Scholar Rock's average media sentiment score of 0.46 beat Maplight Therapeutics' score of 0.34 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scholar Rock is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Maplight Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Maplight Therapeutics	N/A	N/A	N/A

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Scholar Rock beats Maplight Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

CG Oncology currently has a consensus price target of $81.73, suggesting a potential upside of 16.44%. Maplight Therapeutics has a consensus price target of $39.10, suggesting a potential upside of 8.64%. Given CG Oncology's higher possible upside, research analysts plainly believe CG Oncology is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	5 Strong Buy rating(s)	3.13

CG Oncology has higher revenue and earnings than Maplight Therapeutics. CG Oncology is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,532.37	-$160.99M	-$2.33	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Maplight Therapeutics' return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Maplight Therapeutics	N/A	N/A	N/A

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, CG Oncology had 7 more articles in the media than Maplight Therapeutics. MarketBeat recorded 8 mentions for CG Oncology and 1 mentions for Maplight Therapeutics. CG Oncology's average media sentiment score of 0.65 beat Maplight Therapeutics' score of 0.34 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CG Oncology beats Maplight Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Maplight Therapeutics compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Maplight Therapeutics' return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Maplight Therapeutics	N/A	N/A	N/A

In the previous week, Maplight Therapeutics had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 1 mentions for Maplight Therapeutics and 0 mentions for Centessa Pharmaceuticals. Maplight Therapeutics' average media sentiment score of 0.34 beat Centessa Pharmaceuticals' score of 0.00 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Neutral
Maplight Therapeutics	Neutral

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Centessa Pharmaceuticals presently has a consensus target price of $41.33, indicating a potential upside of 2.06%. Maplight Therapeutics has a consensus target price of $39.10, indicating a potential upside of 8.64%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maplight Therapeutics is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	5 Strong Buy rating(s)	3.13

Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Summary

Maplight Therapeutics beats Centessa Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to Erasca?

Erasca (NASDAQ:ERAS) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Erasca currently has a consensus target price of $21.64, suggesting a potential upside of 14.96%. Maplight Therapeutics has a consensus target price of $39.10, suggesting a potential upside of 8.64%. Given Erasca's higher probable upside, equities analysts plainly believe Erasca is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	5 Strong Buy rating(s)	3.13

Maplight Therapeutics' return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Maplight Therapeutics	N/A	N/A	N/A

In the previous week, Erasca had 42 more articles in the media than Maplight Therapeutics. MarketBeat recorded 43 mentions for Erasca and 1 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.34 beat Erasca's score of 0.13 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	4 Very Positive mention(s)	3 Positive mention(s)	32 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Erasca is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Summary

Maplight Therapeutics beats Erasca on 7 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Maplight Therapeutics' return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Maplight Therapeutics	N/A	N/A	N/A

Belite Bio presently has a consensus price target of $203.00, suggesting a potential upside of 32.82%. Maplight Therapeutics has a consensus price target of $39.10, suggesting a potential upside of 8.64%. Given Belite Bio's higher probable upside, equities analysts plainly believe Belite Bio is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	5 Strong Buy rating(s)	3.13

In the previous week, Belite Bio had 5 more articles in the media than Maplight Therapeutics. MarketBeat recorded 6 mentions for Belite Bio and 1 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.34 beat Belite Bio's score of 0.27 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Belite Bio is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Summary

Maplight Therapeutics beats Belite Bio on 7 of the 13 factors compared between the two stocks.

Get Maplight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MPLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MPLT vs. The Competition

Export

Metric	Maplight Therapeutics	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.53B	$3.08B	$4.35B	$12.28B
Dividend Yield	N/A	15.20%	37.90%	9.36%
P/E Ratio	-0.88	13.16	23.61	23.96
Price / Sales	N/A	2,753.10	128.96	112.12
Price / Cash	N/A	25.09	30.17	47.27
Price / Book	3.56	8.60	12.25	6.14
Net Income	-$161.15M	-$34.07M	$120.21M	$331.74M
7 Day Performance	-1.59%	-0.73%	-1.78%	-1.72%
1 Month Performance	24.88%	-1.61%	-2.11%	-1.44%
1 Year Performance	N/A	10.27%	10.69%	16.97%

Maplight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MPLT Maplight Therapeutics	1.5927 of 5 stars	$35.99 -5.0%	$39.73 +10.4%	N/A	$1.61B	N/A	N/A	109	Analyst Forecast
SRRK Scholar Rock	1.9517 of 5 stars	$54.04 +0.5%	$56.00 +3.6%	+29.8%	$6.44B	N/A	N/A	140	News Coverage
CGON CG Oncology	3.2555 of 5 stars	$73.00 +1.7%	$81.73 +12.0%	+168.6%	$6.33B	$5.07M	N/A	61	Analyst Forecast Options Volume
CNTA Centessa Pharmaceuticals	0.7387 of 5 stars	$40.50 flat	$41.33 +2.1%	N/A	$6.27B	N/A	N/A	200
ERAS Erasca	1.8211 of 5 stars	$21.26 +9.0%	$20.64 -2.9%	+1,178.0%	$6.06B	N/A	N/A	120	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MPLT) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maplight Therapeutics (MPLT) Competitors

MPLT vs. SRRK, CGON, CNTA, ERAS, and BLTE

How does Maplight Therapeutics compare to Scholar Rock?

Summary

How does Maplight Therapeutics compare to CG Oncology?

Summary

How does Maplight Therapeutics compare to Centessa Pharmaceuticals?

Summary

How does Maplight Therapeutics compare to Erasca?

Summary

How does Maplight Therapeutics compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maplight Therapeutics (MPLT) Competitors

MPLT vs. SRRK, CGON, CNTA, ERAS, and BLTE

How does Maplight Therapeutics compare to Scholar Rock?

Do analysts prefer SRRK or MPLT?

Does the media refer more to SRRK or MPLT?

Which has stronger valuation & earnings, SRRK or MPLT?

Is SRRK or MPLT more profitable?

Do insiders and institutionals hold more shares of SRRK or MPLT?

Summary

How does Maplight Therapeutics compare to CG Oncology?

Do analysts recommend CGON or MPLT?

Which has stronger valuation and earnings, CGON or MPLT?

Is CGON or MPLT more profitable?

Do institutionals and insiders hold more shares of CGON or MPLT?

Does the media refer more to CGON or MPLT?

Summary

How does Maplight Therapeutics compare to Centessa Pharmaceuticals?

Is CNTA or MPLT more profitable?

Does the media prefer CNTA or MPLT?

Do institutionals & insiders have more ownership in CNTA or MPLT?

Do analysts recommend CNTA or MPLT?

Which has higher valuation and earnings, CNTA or MPLT?

Summary

How does Maplight Therapeutics compare to Erasca?

Do analysts rate ERAS or MPLT?

Is ERAS or MPLT more profitable?

Does the media prefer ERAS or MPLT?

Do institutionals & insiders believe in ERAS or MPLT?

Which has better earnings and valuation, ERAS or MPLT?

Summary

How does Maplight Therapeutics compare to Belite Bio?

Is BLTE or MPLT more profitable?

Do analysts prefer BLTE or MPLT?

Does the media refer more to BLTE or MPLT?

Do institutionals and insiders hold more shares of BLTE or MPLT?

Which has better earnings & valuation, BLTE or MPLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools